Loading clinical trials...

YiqiJiangzhuoHuoxueTongluo Method to Delay the Occurrence of End-stage Renal Disease in Diabetic Kidney Disease--Study1 | Clinical Trials | Clareo Health

NOT_YET_RECRUITING

YiqiJiangzhuoHuoxueTongluo Method to Delay the Occurrence of End-stage Renal Disease in Diabetic Kidney Disease--Study1

Evidence-based Evaluation of Yiqi Jiangzhuo Huoxue Tongluo Method in Delaying the Occurrence of End-stage Renal Disease in Diabetic Kidney Disease--Study 1

NCT07032116•Liu Hongfang

View on ClinicalTrials.gov

Summary

In order to reduce the clinical demand for kidney dialysis rate of Diabetic Kidney Disease（DKD） patients, a bidirectional cohort study of 4472 patients with DKD (Qi deficiency and collateral stasis syndrome) was carried out based on a preliminary DKD cohort of 13,000 patients. The exposure factor was supplementing and reducing the kidney turbidity-Huoxue Tongluo method represented by the addition and subversion of Shenzhuo prescription, and the incidence of end-stage renal disease was the main therapeutic index. Follow-up was conducted for 2 years

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1 in line with Western medicine diagnostic criteria for type 2 diabetic kidney disease ;
•2 18-80 years old, regardless of gender ;
•3 eGFR \> 15ml / ( min · 1.73m2 ) ; the eGFR was calculated according to the chronic kidney disease epidemiology collaboration equation ( CKD-EPI ).
•4 In line with the diagnostic criteria of qi deficiency and collateral stasis syndrome in traditional Chinese medicine ;
•5glycosylated hemoglobin ( HbA1c ) between 7-10 % ;
•6 blood pressure ≤ 160 / 100mmHg ;
•7 to sign the informed consent ;

Exclusion Criteria

•1 combined with other clear renal diseases, such as polycystic kidney disease, glomerulonephritis, renal tumor, etc. ;
•2 patients with a history of recurrent genitourinary tract infection ;
•3 combined with cardiovascular and cerebrovascular, digestive, respiratory, urinary, immune system serious diseases or mental diseases ;
•4 currently in pregnancy, lactation, or pregnancy plan women ;
•5 Patients with type 1 diabetes.
•6 Tumor patients undergoing radiotherapy, chemotherapy or targeted therapy.

Locations (5)

Dongzhimen Hospital of BeijingUniversity of Chinese Medicine

Beijing, Beijing Municipality, China

Guang'anmen Hospital，China Academy of Chinese Medical Sciencescancel

Beijing, Beijing Municipality, China

The First Affiliated Hospital of Sun Yat-sen University

Guangzhou, Guangdong, China

The Affiliated Hospital to ChangChun University of Chinese Medicinecancel

Changchun, Jilin, China

Tianjin Medical University Chu Hsien-I Memorial Hospital

Tianjin, Tianjin Municipality, China

Key Dates

Start Date

August 1, 2025

Primary Completion Date

July 31, 2028

Completion Date

July 31, 2028

Last Updated

June 22, 2025

Enrollment

4,472

ESTIMATED participants

Conditions

Diabetic Kidney Disease (DKD)

Contacts

Qingqing Liu

CONTACT

+8615811362511 125982343@qq.com

Fengyi Cai

CONTACT

+8618810623691 cfy201802@163.com

Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease

NCT07271186

Diabetic Kidney Disease (DKD)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 22, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions